Efficacy and tolerability of milnacipran: An overview

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 4, 1996, Pages 47-51

  Montgomery, S A ^a   Prost, J F ^b   Solles, A ^b   Briley, M ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Adverse events; Antidepressant efficacy; Antidepressants; Milnacipran; Selective serotonin reuptake inhibitors; Therapeutic; Tricyclic

Indexed keywords

MILNACIPRAN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSURIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029848311     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609004-00007     Document Type: Conference Paper

References (24)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. Washington, DC: American Psychiatric Association.
2. Benfield P, Heel RC, Lewis SP (1986) Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:481-508.
3. Covi L, Lipman R, McNair DM, Czerlinski T (1979) Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol 3:521-533.
4. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90: 131-138.
5. Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Dis 18:289-299.
6. DeVane CL (1994) Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 97 (suppl 6A):13S-23S.
7. Edwards JG (1992) Selective serotonin reuptake inhibitors. BMJ 304:1644-1646.
8. Finley PR (1994) Selective serotonin reuptake inhibitors: pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 28:1359-1369.
9. Guy W (Ed) (1976) ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, Maryland: National Institute for Mental Health, Psychopharmacology Research Branch.
10. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62.
11. Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 11 (suppl 4):35-39.
12. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V (1996) Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 11 (suppl 4):29-33.
13. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF (1996) Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (suppl 4): 41-46.
14. Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP (1989) Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 22:77-82.
15. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
16. Montgomery SA, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9 (suppl 4): 33-40.
17. Montgomery SA, Puech A, Prost JF, Solles A, Briley M (1996) Milnacipran, a new double and equipotent noradrenaline and serotonin reuptake inhibitor: an overview of its antidepressant activity and clinical tolerance. J Affect Dis, submitted.
18. Moret C, Charveron M, Finberg JPM, Couziner JP, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219.
19. Potter WZ, Rudorfer MV, Manji H (1991) The pharmacologic treatment of depression. N Engl J Med 325:633-642.
20. Puozzo C, Filaquier C, Briley M (1985) Plasma levels of F 2207, midalcipran, a novel antidepressant, after single oral administration in volunteers. Br J Clin Pharmacol, 20:291P-292P.
21. Raskin A, Schulterbrant J, Reatig N, Rice CE (1969) Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Disord 148:87-98.
22. Richelson E (1983) Antimuscarinic and other receptor-blocking properties of antidepressants. Mayo Clin Proc 58:40-46.
23. Spitzer R, Endicott J, Robins E (1978) Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 34:773-778.
24. Van Praag HM (1984) Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol Bull 20:599-602.